Redox-reactive antiphospholipid antibody differences between serum from Alzheimer's patients and age-matched controls

Autoimmunity

Volumn 42, Issue 8, 2009, Pages 646-652

  McIntyre, John A ^a,b   Wagenknecht, Dawn R ^a   Ramsey, Curtis J ^c  

^a St Francis Hospital   (United States)

^b INDIANA UNIVERSITY   (United States)

^c Curtis Ramsey and Associates   (United States)

Author keywords

Antiphosphatidylethanolamine; Biomarkers cognitive impairment; Dementia; Hemin; Redox reactive autoantibodies; Unmasking autoantibodies

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ADULT; AGED; ALZHEIMER DISEASE; ANTIBODY SPECIFICITY; ARTICLE; AUTOPSY; BLOOD DONOR; BLOOD SAMPLING; BRAIN; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROUPS BY AGE; HUMAN; HUMAN EXPERIMENT; LABORATORY; MALE; OXIDATION; OXIDATION REDUCTION REACTION; SENSITIVITY AND SPECIFICITY; VOLUNTEER;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIBODIES, ANTIPHOSPHOLIPID; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMIN; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PHOSPHOLIPIDS; SENSITIVITY AND SPECIFICITY; SERUM;

EID: 70449433880     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916930903074833     Document Type: Article

References (35)

1. McIntyre JA, Wagenknecht DR, Faulk WP. Autoantibodies unmasked by redox reactions. J Autoimmun 2005;24: 311-317.
2. Cabiedes J, Cabral AR, Alarcon-Segovia D. Hidden antiphospholipid antibodies in normal human sera circulate as immune complexes whose antigen can be removed by heat, acid, hypermolar buffers or phospholipase treatments. Eur J Immunol 1998;7:2108-2114.
3. Lorber M, Shoenfeld Y. Hidden autoantibodies. Clin Rev Allergy Immunol 2000;1:51-58.
4. Tomer Y, Shoenfeld Y. The significance of natural autoantibodies. Immunol Invest 1988;5:389-424.
5. McIntyre JA, Chapman J, Shavit E, Hamilton RL, DeKosky ST. Redox-reactive autoantibodies in Alzheimer's patient's cerebrospinal fluids: Preliminary studies. Autoimmunity 2007;40:390-396.
6. Sultana R, Perluigi M, Butterfield DA. Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Ab (1-42). J Chromatog B 2006;833:3-11.
7. Sayre LM, Perry G, Smith MA. Oxidative stress and neurotoxicity. Chem Res Toxicol 2008;21:172-188.
8. Oomen HA, Wekking EM, de Jong J, Smeenk RJ. Screening psychiatric admissions for anticardiolipin antibody. Psych Res 1995;58(1):83-88, Sep 8.
9. Juby A, Davis P, Genge T, McElhaney J. Anticardiolipin antibodies in two elderly subpopulations. Lupus 6:482-485.
10. Juby AG, Davis P. Prevalence and disease associations of certain autoantibodies in elderly patients. Clin Invest Med 1998;21:4-11.
11. Mosek A, Yust I, Treves TA, Vardinon N, Korczyn AD, Chapman J. Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord 2000;11:36-38.
12. McIntyre JA,Wagenknecht DR,Waxman DW. Frequency and specificities of antiphospholipid antibodies (aPL) in volunteer blood donors. Immunobiology 2003;207:59-63.
13. Steinberg D, Colla P. CART: Tree-structured non- parametric data analysis. San Diego, CA: Salford Systems; 1995.
14. Breiman L, Friedman J, Olshen R, Stone C. Classification and regression trees. Pacific Grove, CA: Wadsworth Publishing Co; 1984.
15. Fisher RA. The use of multiple measurements in taxonomic problems. Ann Eugen 1936;7:179-188.
16. McIntyre JA, Faulk WP. Redox-reactive autoantibodies: Biochemistry, characterization, and specificities. Clin Rev Allerg Immunol 2008, online.
17. Pena-Casanova J. Alzheimer's disease assessment scalecognitive in clinical practice. Int Psychogeriatr 1997;9: 105-114.
18. Tombaugh TN, McIntyre NJ. The mini-mental state examination: A comprehensive review. J Am Geriatr Soc 1992;40:922-935.
19. Lopez OL, Becker JT, Klunk W, Saxton J, Hamilton RL, Kaufer DI, Sweet RA, Meltzer CC, Wisniewski S, Kamboh MI, DeKosky ST. Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology. 2000;55:1854-1862. (Pubitemid 32103968)
20. Lopez OL, Becker JT, Klunk W, Saxton J, Hamilton RL, Kaufer DI, Sweet RA, Meltzer CC, Wisniewski S, Kamboh MI, DeKosky ST. Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: II. Neurology. 2000;55:1863-1869. (Pubitemid 32103969)
21. Consensus report of the working group on molecular and biochemical markers of Alzheimer's disease The Ronald and Nancy Reagan Research Institute of Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109-116.
22. Formichi P, Battisti C, Radi E, Federico A. Cerebrospinal fluid tau Ab, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J Cell Physiol 2006;208: 39-46.
23. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007;64:354-362.
24. Kawarabayashi T, Shoji M. Plasma biomarkers of Alzheimer's disease. Curr Opin Psych 2008;21:260-267.
25. Bailey P. Biological markers in Alzheimer's disease. Can J Neurol Sci 2007;34:S72-S76.
26. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger- Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, SternY, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDSADRDA criteria. Lancet Neurol 2007;6:734-746.
27. Jellinger KA, Janetzky B, Attems J, Kienzl E. Biomarkers for early diagnosis of Alzheimer's disease: 'ALZheimer ASssociated gene' - a new blood biomarker. J Cell Mol Med 2008; 12:1094-1117.
28. Ray S, BritschgiM, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Med 2007;11:1359-1362.
29. Blennow M, de Leon H, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387-403.
30. McIntyre JA. The appearance and disappearance of antiphospholipid antibodies subsequent to oxidation-reduction reactions. Thromb Res 2004;114:579-587.
31. McIntyre JA, Wagenknecht DR, Faulk WP. Redox-reactive autoantibodies: Detection and physiological relevance. Autoimmun Rev 2006;5:76-83.
32. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW, Heath D, Yamazaki Y, Flax J, Krenitsky KF, Sparks DL, Lerner A, Friedland RP, Kudo T, Kamino K, Morihara T, Takeda M, Wood PL. Peripheral ethanolamine plasmalogen deficiency: A logical causative factor in Alzheimer's disease and dementia. J Lipid Res 2007;48:2485-2498.
33. Ginsberg L, Rafique S, Xuereb JH, Rapoport SI, Gershfeld NL. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Brain Res 1995;698:223-226.
34. Qamar T, Gharavi AE, Levy RA, Lockshin MD. Lysophosphatidylethanolamine is the antigen to which apparent antibody to phosphatidylethanolamine binds. J Clin Immunol 1990;10:200-203.
35. Kerr E, Craig D, McGuinness B, Dynan KB, Fogarty D, Johnston JA, Passmore AP. Reduced estimated glomerular filtration rate in Alzheimer's disease. Int J Geriatr Psych 2009, (in press).